Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Abstract
AIMS: A variety of basal insulin preparations are used to treat patients with type 2 diabetes mellitus (T2DM). We aimed to summarize scientific evidence on relative efficacy and safety of insulin glargine (IGlar) and other insulins in T2DM. METHODS: A systematic review was carried out in major medical databases up to December 2012. Relevant studies compared efficacy and safety of IGlar, added to oral drugs (OAD) or/and in combination with bolus insulin, with protamine insulin (NPH) or premixed insulin (MIX) in the same regimen, as well as with insulin detemir (IDet), in T2DM. Target HbA1c level without hypoglycemic events was considered the primary endpoint. RESULTS: Twenty eight RCTs involving 12,669 T2DM patients followed for 12-52 weeks were included in quantitative analysis. IGlar + OAD use was associated with higher probability of reaching target HbA1c level without hypoglycemia as compared to NPH + OAD (RR = 1.32 [1.09, 1.59]) or MIX without OAD (RR = 1.61 [1.22, 2.13]) and similar effect as IDet + OAD (RR = 1.07 [0.87, 1.33]) and MIX + OAD (RR = 1.09 [0.86, 1.38]). IGlar + OAD demonstrated significantly lower risk of symptomatic hypoglycemia as compared to NPH + OAD (RR = 0.89 [0.83, 0.96]), MIX + OAD (RR = 0.75 [0.68, 0.83]) and MIX without OAD(RR = 0.75 [0.68, 0.83]), but not with IDet + OAD (RR = 0.99 [0.90, 1.08]). In basal-bolus regimens, IGlar demonstrated similar proportion of T2DM patients achieving target HbA1c as compared to NPH (RR = 1.14 [0.91, 1.44]) but higher than MIX (RR = 1.26 [1.12, 1.42) or IDet (RR = 1.38 [1.11, 1.72]). The risk of severe hypoglycemia was lower in IGlar than in NPH (RR = 0.77 [0.63, 0.94]), with no differences in comparison with MIX (RR = 0.74 [0.46, 1.20]) and IDet (RR = 1.10 [0.54, 2.25]). IGlar + OAD has comparable safety profile to NPH, with less frequent adverse events leading to treatment discontinuation than MIX + OAD (RR = 0.41 [0.22, 0.76]) and IDet + OAD (RR = 0.40 [0.24, 0.69]). Also severe adverse reactions were less common for IGlar + OAD when compared to MIX + OAD (RR = 0.71 [0.52; 0.98]). CONCLUSION: For the majority of examined efficacy and safety outcomes, IGlar use in T2DM patients was superior or non-inferior to the alternative insulin treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Today, more effective and better tolerated drugs are available [[205], [206], [207]].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [206]
In the citing paper
“Pharmacotherapy for diabetes mellitus began with several drugs that were poorly tolerated or that had adverse side effects.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 2×
“Search strategy Following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, clinical evidence was identified through a systematic search of major databases of medical information, including Medline (via PubMed), EMBASE and the Cochrane Central Register of Controlled Trials [35…”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Higher number of granted points reflected higher credibility of a clinical trial [37].”
BackgroundZhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Research works printed but not linked: 1
- National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Royal College of Physicians, London. http://www.nice.org.uk/guidance/cg66 21678628
Cited by
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O’Neil, P. M. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 239
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.
Farrell, B. J., Black, C. D., Thompson, W., McCarthy, L. M., Rojas‐Fernandez, C. H., Lochnan, H. A., Shamji, S., Upshur, R. E. G., Bouchard, M., & Welch, V. A. (2017) · Europe PMC (PubMed Central) · Cited by 213
Semlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80
Lipska, K. J., Parker, M. M., Moffet, H. H., Huang, E. S., & Karter, A. J. (2018) · JAMA · doi:10.1001/jama.2018.7993 · Cited by 76
Lucidi, P., Porcellati, F., Andreoli, A. M., Carriero, I., Candeloro, P., Cioli, P., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes Care · doi:10.2337/dc15-0801 · Cited by 81
“insulin component might contribute to the elevated risk for hypoglycemia of NPH insulin–based premixed formulations (23) in addition to its PK/PD (20).”
(2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00240-0 · Cited by 67
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Freemantle, N., Chou, E., Frois, C., Zhuo, D., Lehmacher, W., Vlajnic, A., Wang, H., Chung, H.-W., Zhang, Q., Wu, E., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009421 · Cited by 60
Insulin Therapy in Type 2 Diabetes
Aschner, P. J. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001088 · Cited by 56
Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194801 · Cited by 41
Godman, B., Haque, M., Leong, T. D. D., Allocati, E., Kumar, S., Islam, S., Charan, J., Akter, F., Kurdi, A. B., Vassalo, C., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.671961 · Cited by 52
Vargas‐Uricoechea, H. (2018) · Journal of Diabetes Research · doi:10.1155/2018/2052101 · Cited by 41
Dalal, M. R., Kazemi, M. R., Ye, F., & Xie, L. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0592-x · Cited by 37
“hypoglycemia appears to be similar for Gla-100 and insulin detemir on the basis of data from clinical trials [6] and real-world observational studies [7, 8].”
Background100 years on: the impact of the discovery of insulin on clinical outcomes
Buse, J. B., Davies, M. J., Frier, B. M., & Philis‐Tsimikas, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002373 · Cited by 43
“38 39 This advance also heralded the advent of the treat- to-target approach, making patients’ self-titration of basal insulin more accessible.”
BackgroundBetônico, C. C., Titan, S. M. O., Lira, A., Pelaes, T. S., Correa-Giannella, M. L. C., Nery, M., & Queiroz, M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.07.011 · Cited by 32
Owens, D. R., Bailey, T. S., Fanelli, C. G., Yale, J., & Bolli, G. B. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.11.004 · Cited by 36
“as neutral protamine Hagedorn (NPH) insulin [9-12] and Lente insulin [13,14].”
BackgroundMannucci, E., Caiulo, C., Naletto, L., Madama, G., & Monami, M. (2021) · Endocrine · doi:10.1007/s12020-021-02889-6 · Cited by 30
Arvanitakis, K., Koufakis, T., Kalopitas, G., Papadakos, S. P., Kotsa, K., & Germanidis, G. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102935 · Cited by 35
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 41
Haque, M., Islam, S., Kamal, Z. M., Akter, F., Jahan, I., Rahim, M. J., Sultana, N., Alam, A. M., Murshid, M. E., Khan, M. A., et al. (2021) · Hospital Practice · doi:10.1080/21548331.2021.1906083 · Cited by 26
“Alongside this, the authorities in Bangladesh need to increase the number of ambulatory care facilities to better diagnose and manage patients with diabetes in the first place given current concerns as well as rising rates of diabetes [16].”
BackgroundShafie, A. A., Ng, C. H., Tan, Y. P., & Chaiyakunapruk, N. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0456-2 · Cited by 31
“Reviews of insulin analogues have only covered the side effects [11, 12], clinical efficacy and safety of long-acting insulin analogues in T1DM [13, 14] or in T2DM [15], and reviews of the cost effectiveness of insulin analogues have primarily focused on a single type of insulin [16–18] or on long-acting insulin analo…”
BackgroundGodman, B., Haque, M., Kumar, S., Islam, S., Charan, J., Akter, F., Kurdi, A. B., Allocati, E., Bakar, M. A., Rahim, M. J., et al. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1946024 · Cited by 30
Tien, K., Hung, Y., Chen, J., Chen, C., Wang, C., Hwu, C., Huang, Y., Hsiao, P., Tu, S., Wang, C., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12984 · Cited by 24
Sardina, P. D., Martin, J. S., Avery, J. C., & Braith, R. W. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0866-9 · Cited by 26
“Alternative treatments such as dipeptidyl peptidase-4 (DPP-4) inhibitors [4] and insulin glargine with neutral protamine Hagedorn (NPH) insulin [5] have been utilized, but alternative treatments for T2DM should continue to be explored.”
BackgroundKis, J. T., Nagy, G., & Kovács, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01128-5 · Cited by 24
“The superiority of the insulin glargine ? oral antidiabetics drugs (OADs) combination over the neutral protamine Hagedorn (NPH) insulin ? OAD combination or premixed insulin preparations has been demonstrated [2].”
BackgroundInsulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults*
Strandberg, A. Y., Khanfir, H., Mäkimattila, S., Saukkonen, T. T., Strandberg, T. E., & Hoti, F. J. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1278302 · Cited by 19
“Weighting each subject with the inverse of the PS results in a “pseudo”population where the distributions of the potential confounders (covariates included in PS model) are balanced between exposure groups (17).”
BackgroundBhatia, A., Tawade, S., Mastim, M. A., Kitabi, E. N., Gopalakrishnan, M., Shah, M., Yeshamaina, S., Gobburu, J. V. S., Sahib, M. K., Thakur, D., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1113-3 · Cited by 20
“Consequently, compared with protamine insulin (NPH) or premixed insulins (NPH + regular) or human insulin treatment (NPH before dinner and regular insulin before meals), insulin glargine has higher probability of reaching target HbA1c level without hypoglycemic events and with less glycemic variability [8, 9].”
BackgroundBartal, M. F., Ward, C., Blackwell, S. C., Cornthwaite, J. A. A., Zhang, C., Refuerzo, J., Pedroza, C., Lee, K. H., Chauhan, S. P., & Sibai, B. M. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.223 · Cited by 18
Monami, M., Ragghianti, B., Zannoni, S., Vitale, V., Nreu, B., & Mannucci, E. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0732-1 · Cited by 19
“Basal insulin analogs are currently preferred to NPH or premixed insulin, due to their lower hypoglycemic risk [2, 3].”
Prescription patterns and costs of antidiabetic medications in a large group of patients
Gaviria‐Mendoza, A., Sánchez‐Duque, J. A., Medina-Morales, D. A., & Machado‐Alba, J. E. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.11.002 · Cited by 19
Godman, B., Władysiuk, M., McTaggart, S., Kurdi, A. B., Allocati, E., Jakovljević, M., Kalemeera, F., Hoxha, I., Nachtnebel, A., Sauermann, R., et al. (2021) · BioMed Research International · doi:10.1155/2021/9996193 · Cited by 18
Zhou, J., Zheng, F., Guo, X., Yang, H.-Z., Zhang, M., Tian, H., Guo, L., Li, Q., Mo, Y., & Jia, W. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2661 · Cited by 15
Dalal, M. R., Kazemi, M. R., & Ye, F. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1248911 · Cited by 14
Msane, S., Khathi, A., & Sosibo, A. M. (2024) · Nutrients · doi:10.3390/nu16162692 · Cited by 22
“…to regulate blood glucose levels and alleviate symptoms of T2DM by replenishing or complementing the body’s natural insulin production from the pancreas [55,56]. levels and alleviate symptoms of T2DM by replenishing or complementing the body’s natural insulin production from the pancreas [55,56].”
BackgroundComparative effectiveness and safety of different basal insulins in a real-world setting
Ji, L., Zhang, P., Zhu, D., Lu, J., Guo, X., Wu, Y., Li, X., Ji, J., Jia, W., Yang, W., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12920 · Cited by 13
“Similar results were observed in previous RCT studies.(7,10,33,34) In the ITT population, the effect of adding 1 specific BI may be either diluted or strengthened by regimen change or by adding prandial insulin during follow-up, which might impact comparison among different insulin treatments.”
ResultReal-world therapeutic benefits of patients on insulin glargine versus NPH insulin
Fießelmann, A., Wiesner, T., Fleischmann, H., & Bramlage, P. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0862-0 · Cited by 14
Lega, I. C., Yale, J.-F., Chadha, A., Paty, B., Roscoe, R., Snider, M., Steier, J., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.08.003 · Cited by 12
Sun, D., Zhang, X., & Hou, X.-X. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0132 · Cited by 13
Seufert, J., Borck, A., & Bramlage, P. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000679 · Cited by 12
“38 Similarly, pharmacodynamic studies have demonstrated very little difference in duration of action.”
InfluentialZhang, T., Ji, L., Gao, Y., Zhang, P., Zhu, D., Li, X., Ji, J., Zhao, F., Zhang, H., & Guo, X. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0111 · Cited by 11
“Since China has the largest number of patients with diabetes in the world, more data are needed to guide the use of BI in Chinese population with T2D.”
InfluentialVargas‐Uricoechea, H., & Pablo, F. J. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.001 · Cited by 11
Opanga, S. A., Njeri, L. W., Kimonge, D., Godman, B., & Oluka, M. N. (2021) · Scholars Academic Journal of Pharmacy · doi:10.36347/sajp.2021.v10i04.002 · Cited by 9
“With respect to insulins, we have seen the development of long-acting insulin analogues to reduce rates of hypoglycaemia, especially nocturnal hypoglycaemia, and improve adherence through improved patient comfort [2,46-53].”
BackgroundManagement of hyperglycaemia in people with obesity
Mourougavelou, V., & Chowdhury, T. A. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0135 · Cited by 11
Bohn, B., Bramlage, P., Wagner, C., Kaltheuner, M., Welp, R., Sziegoleit, S., Zimmermann, A., Reuter, H. M., Hummel, M., Gloyer, J., et al. (2017) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-017-0589-8 · Cited by 9
Brian, G., Tubić, B., Allocati, E., Władysiuk, M., McTaggart, S., Kurdi, A. B., Haque, M., MacBride‐Stewart, S., Kalemeera, F., Massele, A. Y., et al. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.120306 · Cited by 10
“Long-acting insulin analogues were developed to reduce hypoglycemia, including nocturnal hypoglycemia, among patients with diabetes requiring insulin (Rys et al., 2015; Tricco et al., 2021).”
Switching basal insulins in type 2 diabetes: practical recommendations for health care providers
Anderson, S. L., Trujillo, J. M., Anderson, J. E., & Tanenberg, R. J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1419048 · Cited by 11
Basal insulin analogs versus Neutral Protamine Hagedorn for type 2 diabetics
Fishel Bartal, M., Ward, C., Refuerzo, J. S., Ashimi, S. S., Joycelyn, C. A., Chen, H.-Y., Chauhan, S. P., & Sibai, B. M. (2020) · American Journal of Perinatology · doi:10.1055/s-0039-1694733 · Cited by 8
Zhou, F. L., Nicholls, C. J., Xie, L., Wang, Y., Vaidya, N., & Meneghini, L. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.73 · Cited by 7
Haque, M., Salequl, I., Rabiu, A. A., Haruna, S. I., Opanga, S. A., Mahmood, K. Z., Farhana, A., & Brian, G. (2021) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2021.110720 · Cited by 9
“Bangladesh, in view of their documented benefits in reducing rates of hypoglycemia, especially nocturnal hypoglycemia, as well as improving adherence to insulin administration through improved patient comfort (Chan et al., 2021; Ewen et al., 2019; Haque et al., 2021a; Laranjeira et al., 2018; Monami et al., 2009; Pede…”
Mellor, J., Kuznetsov, D., Heller, S. R., Gall, M.-A., Rosilio, M., Amiel, S. A., Ibberson, M. R., McGurnaghan, S. J., Blackbourn, L. A. K., Berthon, W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06177-6 · Cited by 12
“Our data replicate some well-recognised associations for hypoglycaemia, validating our methodology, such as worse hypoglycaemia risk with longer diabetes duration [15] and less frequent hypo-glycaemia with insulin analogue [16–20].”
Jensen, M. H., Hejlesen, O. K., & Vestergaard, P. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14263 · Cited by 8
Wang, Y., Zhou, Y., Ding, J., Li, X., Guo, F., Zhang, J., & Ding, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.962201 · Cited by 8
“, 2005) and its higher probability of reaching target HbA1c level without hypoglycemic events and with less glycemic variability (PerezMaraver et al., 2013; Rys et al., 2015).”
BackgroundDavis, T. M. E., Bruce, D. G., Finn, J., Curtis, B. H., Barraclough, H., & Davis, W. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13568 · Cited by 9
“NT-proBNP, pg/mL 77 (18-328) 270 (54-1350) <0.”
Fritsche, A., Anderten, H., Pfohl, M., Pscherer, S., Borck, A., Pegelow, K., Bramlage, P., & Seufert, J. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000668 · Cited by 6
“This addition of once-daily long-lasting basal insulin to existing OAD treatment is known as basal-supported oral therapy (BOT), and has been associated with greater target attainment and a lower risk of hypoglycemia compared with the addition of less-long-acting insulins (such as neutral protamine Hagedorn (NPH) and…”
BackgroundTavares, R., Duclos, M., Brabant, M.-J., Checchin, D., Bosnic, N., Turvey, K., & Terres, J. A. R. (2016) · Acta Diabetologica · doi:10.1007/s00592-015-0823-z · Cited by 6
“Further, NPH insulin is associated with an increased risk of hypoglycemia relative to other basal insulin regimens [26, 27], independent of its greater dosing frequency [28].”
BackgroundOne Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
Evans, M., Morgan, A. R., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01061-7 · Cited by 7
Intensive Insulin Therapy (Basal-Bolus)
Chico, A. I., & Corcoy, R. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001152 · Cited by 6
Agudo-Tabuenca, A., Gimeno-Orna, J. A., & Sáenz-Abad, D. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.01.008 · Cited by 9
Yang, C.-T., Li, K.-Y., Yang, C., Ou, H., & Kuo, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83253-6 · Cited by 6
“(2) Matching steps: (1) Step 1: matched by the cohort entry time (i.”
BackgroundMethodInfluentialMardare, I., Campbell, S., Meyer, J. C., Sefah, I. A., Massele, A. Y., & Godman, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794363 · Cited by 7
Synthesizing evidence from clinical trials with dynamic interactive argument trees
Sanchez-Graillet, O., Witte, C., Grimm, F., Grautoff, S., Ell, B., & Cimiano, P. (2022) · Journal of Biomedical Semantics · doi:10.1186/s13326-022-00270-8 · Cited by 6
“We first formalized the evidence of each of the trials considered in the respective systematic reviews for glaucoma and T2DM [19, 20] as described in the section “The C-TrO ontology and knowledge base”.”
MethodResultDetemir vs Glargine: Comparison of Inpatient Glycemic Control
Capson, J., Cade, K., & Avanesyan, A. (2019) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2019.014 · Cited by 5
Wolnik, B., de Wiza, D., Szczepanik, T., Syta, A., & Klupa, T. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8751348 · Cited by 5
“Switching from human neutral protamine Hagedorn (NPH) basal insulin to long-acting, first-generation basal insulin analogues significantly decreases the risk of hypoglycaemia in patients with T2DM [9].”
BackgroundSelf-citationKumar, K., Chowdhury, S., Bantwal, G., Unnikrishnan, A., Kalra, S., Aggarwal, S., Singh, A. K., Pandit, K., Shukla, R., Vishwanathan, V., et al. (2024) · Cureus · doi:10.7759/cureus.60983 · Cited by 5
“A steadily expanding body of evidence has allowed insulin glargine to address and alleviate the commonly held concerns linked to the utilization of basal insulin for managing diabetes [35-39].”
BackgroundBjekić-Macut, J., Živković, T. B., & Kocić, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0378-4 · Cited by 4
“Meta-analyses of clinical trials reported efficacy outcomes with basal insulin analogues to be mostly non-inferior or better than with other insulins, while the incidence of hypoglycemia (in particular nocturnal) was reduced [7, 8].”
MethodBrunetti, V. C., Yu, O. H. Y., Platt, R. W., & Filion, K. B. (2021) · Diabetic Medicine · doi:10.1111/dme.14603 · Cited by 4
Agudo-Tabuenca, A., Gimeno-Orna, J. A., & Sáenz-Abad, D. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2019.01.007 · Cited by 9
Biosimilar of analogue of insulin glargin: proven safety, effectiveness, interchangeability
Bulgakova, S. V., Николаевна, С. Е., Sharonova, L. A., Dolgikh, Y. A., & Kosareva, O. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-23-207-214 · Cited by 4
Mishriky, B. M., Cummings, D. M., Tanenberg, R. J., & Pories, W. J. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1533381 · Cited by 6
“Although the incidence and severity of hypoglycemia is expected to differ between different types of insulin, a meta-analysis separately comparing insulin glargine to either NPH or premixed insulin without OAD or insulin degludec showed no significant difference in the overall risk of hypoglycemia in all comparisons […”
BackgroundInsulin Pharmacodynamics, Pharmacokinetics, and Insulin Regimens
Kelkar, S., Muley, S., & Ambardekar, P. (2019) · Springer eBooks · doi:10.1007/978-981-13-7705-1_11 · Cited by 3
Deerochanawong, C., Leelawattana, R., Kosachunhanun, N., & Tantiwong, P. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420935930 · Cited by 3
Sethi, B. K., Unnikrishnan, A., Ayyar, V. S., Jabbar, P. K., Ganguly, K. K., Bhandari, S., Rastogi, A., Mukherjee, R., Sundaram, V., & Asirvatham, A. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01284-2 · Cited by 3
Živković, T. B., Djindjić, B., Toljić, D. Ž. Š., Vulovic, K. M., Udovičić, D. L., & Zdravković, D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0530-1 · Cited by 3
Evolution of biosynthetic human insulin and its analogues for diabetes management
Francis, D., Chacko, A. M., Anoop, A., Nadimuthu, S., & Venugopal, V. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.06.004 · Cited by 2
Chraibi, A., Seqat, M., & Nejjari, C. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30253-4 · Cited by 2
Comparative efficacy and safety of basal insulins: A review
Vargas‐Uricoechea, H., & Montoya, P. A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102318 · Cited by 2
Is NPH associated with fewer adverse events than analog basal insulin for adults with T2D?
Lyon (2021) · The Journal of Family Practice · doi:10.12788/jfp.0191 · Cited by 2
Vargas‐Uricoechea, H., & Frías, J. P. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.014 · Cited by 2
Human Insulin Versus Insulin Analogues: A True Companion Forgotten
Abdi, H. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.97054 · Cited by 2
“These findings were confirmed in a more recent systematic review (8).”
BackgroundAlmeida, P. H. R. F., Godman, B., Nogueira, V. D. S. N., de Lemos, L. L. P., Acúrcio, F. D. A., Guerra, A. A., de Araújo, V. E., Almeida, A. M., & Álvares-Teodoro, J. (2022) · Clinical Diabetes · doi:10.2337/cd21-0068 · Cited by 1
Expanded Basal Insulin Options for Type 2 Diabetes Mellitus
Olin, J. L., & Harris, K. B. (2016) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.07.011 · Cited by 2
Raghavan, A., Nanditha, A., Satheesh, K., Susairaj, P., Vinitha, R., Nair, D. R., Snehalatha, C., & Ramachandran, A. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.01.006 · Cited by 4
Pakdaman, M., Akbari, R., Dehghan, H. R., Valagohar, R., Rostami, P., & Namayandeh, M. (2019) · Health Technology Assessment in Action · doi:10.5812/htaa.86421 · Cited by 1
“(34) by reviewing clinical trials on the effectiveness insulin pen demonstrated that using glargine insulin pen versus NPH insulin pen decreases HbA1c with no significant reduction in blood glucose.”
BackgroundFarrell, B. J., Black, C. D., Thompson, W., McCarthy, L. M., Rojas‐Fernandez, C. H., Lochnan, H. A., Shamji, S., Upshur, R. E. G., Bouchard, M., & Welch, V. A. (2017) · Europe PMC (PubMed Central) · Cited by 2
Dzida, G. J., & Szczepanik, T. (2021) · Clinical Diabetology · doi:10.5603/dk.a2021.0015 · Cited by 1
“Large studies have shown that insulin glargine effectively lowers HbA1c without increasing hypoglycemia risk in patients receiving oral antidiabetic drugs [8] or who switch from NPH insulin [9].”
BackgroundKodama, S., Fujihara, K., Ishiguro, H., Matsubayashi, Y., Kitazawa, M., Iwanaga, M., Yamada, T., Kato, K., Nakagawa, Y., Tanaka, S., et al. (2023) · Journal of Investigative Medicine · doi:10.1177/10815589221149188 · Cited by 1
Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran
Nosrati, M., Fariman, S., Saiyarsarai, P., & Nikfar, S. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01209-1 · Cited by 2
Betônico, C. D. C. R. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-05042017-153224 · Cited by 1
Challenges in Choosing a Medication for Type 2 Diabetes
Rodríguez‐Gutiérrez, R., Salcido‐Montenegro, A., Elizondo-Plazas, A., & González‐González, J. G. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0166 · Cited by 1
Davis, T. M. E., Chubb, S. A. P., Curtis, B. H., Barraclough, H., & Davis, W. A. (2017) · Internal Medicine Journal · doi:10.1111/imj.13710
Ye, Z., Xin, Q., Jiang, X., & Sun, L. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0621-6
Derakhshan, P., Khatibi, A., Faiz, S. H. R., Rahimzadeh, P., & Nouri, N. (2021) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.35.31 · Cited by 1
General Preoperative Considerations and Preparation of the Patient for Surgery
Bojar, R. M. (2020) · Wiley eBooks · doi:10.1002/9781119582540.ch3
Análogos de la insulina. ¿Cuál es su lugar en la terapéutica?
Guillén, E., & Callol, J.-A. V. I. (2022) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2021.09.010
Kazakou, P., Paschou, S. Α., Mitropoulou, M., Vasileiou, V., Sarantopoulou, V., & Anastasiou, E. (2022) · Research Square · doi:10.21203/rs.3.rs-1921427/v1
Fatima, K., Siddiqi, A. K., Shakil, S., Akhtar, S. E., QURAISHY, M. S., Siddiqui, K., RAFIQUE, E., & Maniya, M. T. (2023) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.23.05318-6 · Cited by 1
Real-World Analysis of Long-Acting and NPH-Containing Insulins on Glycemic Control
Hale, G. M., Marcellus, V., Benny, T., Moreau, C. S., Rosario, E., & Pérez, A. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.42
Kuppirala, S. C., & Reddy, K. S. (2026) · Chromatographia · doi:10.1007/s10337-026-04500-4
“The long-acting recombinant human insulin analogue, insulin glargine, has been extensively used in clinical practice due to its prolonged and stable pharmacokinetic profile, allowing once-daily dosing and improved glycemic control compared to regular human insulin [7 –9].”
Metadata
- Authors
- Rys, P., Wojciechowski, P., Rogoz-Sitek, A., Niesyczyński, G., Lis, J., Syta, A., & Malecki, M. T.
- Affiliations
- Sanofi (France) (FR)
- Jagiellonian University (PL)
- Corresponding author
- Malecki, Maciej T.
- Venue
- Acta Diabetologica
- Published
- 2015-01-14
- Volume
- 52
- Issue
- 4
- Pages
- 649-662
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- PMC
- PMC4506471
- OpenAlex
- W2016846562
- Cited by
- 101
- References
- 92
- Citations by year
- 2026: 2 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 18 · 2020: 7 · 2019: 14 · 2018: 14 · 2017: 11 · 2016: 8 · 2015: 4
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Diabetologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Funders
- Sanofi
- Novo Nordisk
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, NPH insulin, premixed insulin, insulin detemir, type 2 diabetes, basal insulin, HbA1c, glycemic control, hypoglycemia, oral antidiabetic drugs, insulin safety, insulin analogues, insulin sensitivity
- MeSH terms
- Insulin Glargine, Insulin Detemir, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin, Isophane, Randomized Controlled Trials as Topic, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
